Cancer physician groups have become increasingly vocal in recent weeks about national shortages in key medications, including longtime generic drugs like carboplatin and cisplatin.
The result, published simultaneously in the journal JAMA, suggests that donanemab is at least as effective as the newly approved drug Leqembi (lecanemab), which was found to reduce progression by about 27%.
The FDA on Monday approved nirsevimab, a single shot of antibodies that was shown in clinical trials to lower the need for medical care from RSV for babies by 70-75%.
DTx Pharma focuses on developing therapies targeting disorders affecting the nervous system, which aligns with Novartis’ efforts to expand its neuroscience pipeline.